RVTY Stock Snapshot Price, market cap, P/E, EPS, ROE, debt/equity, 52-week range

03
Price $151.53
Market Cap (MRQ) $16.91B
P/E 46.7
EPS $2.07
Revenue $2.86B
Div Yield 0.30%
ROE 3.3%
Debt/Equity (MRQ) 0.4
52W Range $81–$158

RVTY Stock Price Chart Daily OHLCV with technical indicators — pan, zoom, and customize your view

04
range
bars

Bar granularity adapts to the selected period — hover the chart to see open/high/low/close for a bar.

Stock splits 4
Ex-date Split Type
June 4, 2001 2-for-1 Forward
May 11, 1992 2-for-1 Forward
Feb. 2, 1982 2-for-1 Forward
Feb. 4, 1980 2-for-1 Forward

About Revvity, Inc. Common Stock Company overview from Wikipedia

05 · wikidata

PerkinElmer, Inc., previously styled Perkin-Elmer, is an American global corporation that was founded in 1937 and originally focused on precision optics. Over the years it went into and out of several different businesses via acquisitions and divestitures; these included defense products, semiconductors, computer systems, and others. By the 21st century, PerkinElmer was focused in the business areas of diagnostics, life science research, food, environmental and industrial testing. Its capabilities include detection, imaging, informatics, and service. It produced analytical instruments, genetic testing and diagnostic tools, medical imaging components, software, instruments, and consumables for multiple end markets. PerkinElmer was part of the S&P 500 Index and operated in 190 countries.

Over its history, PerkinElmer has been split in two twice. In 1999, PerkinElmer merged with EG&G, with the ongoing Analytical Instruments Division of Perkin-Elmer keeping that name, while the life sciences division of the company became the separate PE Corporation. In 2022, a split of PerkinElmer resulted in one part, comprising applied, food and enterprise services businesses, being sold to the private equity firm New Mountain Capital for $2.45 billion and thus no longer being public but kept the PerkinElmer name. The other part, comprising life sciences and diagnostics businesses, remained public but required a new name, which in 2023 was announced as Revvity, Inc.

History

Founding

Richard Perkin was attending the Pratt Institute in Brooklyn to study chemical engineering, but left after a year to try his hand on Wall Street. Still interested in the sciences, he gave public lectures on various topics. Charles Elmer ran a firm that supplied court reporters and was nearing retirement when he attended one of Perkin's lectures on astronomy being held at the Brooklyn Institute of Arts and Sciences.

The two struck up a friendship over their shared interest in astronomy, and eventually came up with the idea of starting a firm to produce precision optics. Perkin raised US$15,000 from his relatives, while Elmer added US$5,000, and the firm was initially set up as a partnership on 19 April 1937. Initially, they worked from a small office in Manhattan, but soon opened a production facility in Jersey City. They incorporated the growing firm on 13 December 1939. A further move to Glenbrook in Connecticut in 1941 was quickly followed by another move to Norwalk, Connecticut, where the company remained until 2000. The opening of World War II led to significant expansion as the company produced optics for range finders, bombsights, and reconnaissance systems. This work led to the U.S. Navy awarding them the first "E" for Excellence award in 1942.

Perkin-Elmer retained a strong presence in the military field through the 1960s and at the same time was significantly involved with OAO-3 a 36-inch Ultra Violet Space Telescope and Skylab. They contributed to the Apollo program by development of a CO2 sensor that was, however, supplanted by a Coleman Instruments product. PE at the Norwalk plant also conducted one of the first researches into computer-digital enhancement of scanned images, contracted for application to the Corona spy satellite, film imagery. They were a primary supplier of the optical systems used in many reconnaissance platforms, first in aircraft and high-altitude balloons, and then in reconnaissance satellites. A significant advance was 1955's Transverse Panoramic Camera, which took images on 12 by 14 ft (3.7 by 4.3 m) wide frames that provided single-frame images from horizon to horizon from an aircraft flying at 40,000 ft altitude. Such systems remained a major part of the company's income, capped by the installation of laser retroreflectors on the Moon as part of the Apollo 11 mission.

Elmer died at age 83 in 1954, and the company began trading shares over the counter. The company was listed on the New York Stock Exchange on 13 December 1960. Perkin remained as president and CEO until June 1961, when Robert Lewis, previously of Argus Camera and Sylvania Electric Products, took over these roles. Perkin remained the chairman of the board until his death in 1969.

Semiconductor manufacturing

In 1967, the U.S. Air Force asked Perkin-Elmer to produce an all-optical "masking" system for semiconductor fabrication. Previous systems used a pattern, the "mask", which was pressed onto the surface of the silicon wafer as part of the photolithography process. Small bits of dirt or photoresist would stick the mask and ruin the patterning for subsequent chips, and it was not uncommon for the vast majority of the chips from a given wafer to malfunction. The Air Force, which by the late 1960s was highly reliant on integrated circuits, desired a more reliable system.

Perkin-Elmer responded with the Microprojector, which was essentially a large photocopier system. The mask was placed in a holder and never touched the surface of the chip. Instead, the image was projected onto the surface. Making this work required a complex 16-element lens system that focussed a narrow range of wavelengths of light onto the mask. The remainder of the light from the 1,000 watt mercury-vapor lamp was filtered out. PE also developed a micro-densitometer in 1967 that scanned micro-chips for quality control

Harold Hemstreet was convinced that the concept could be simplified, and Abe Offner began the development of a system using mirrors instead of lenses, which did not suffer from the multispectral focussing problems of lenses. The result of this research was the Projection Scanning Aligner, or Micralign, which made chip making an assembly-line task and improved the number of working chips from perhaps 10% to 70% overnight. Chip prices plummeted as a result, with examples like the MOS 6502 selling for about US$20 while the previous generation of designs like the Motorola 6800 sold for around US$250.

The Micralign was so successful that Perkin-Elmer became the largest single vendor in the chip space in three years. In spite of this success, the company was largely a has-been by the 1980s due to their late response to the introduction of the stepping aligner, which allowed a single small mask to be stepped across the wafer, rather than requiring a single large mask covering the entire wafer. The company never regained their lead, and sold the division to The Silicon Valley Group.

Lab equipment

Perkin Elmer was a leading developer and supplier of lab analytic equipment from the 1950's. By the 1960's the Norwalk/Wilton, CT facilities were developing and producing a wide variety of instruments including multi-spectral spectrometers (IR, visible, UV), gas chromatographs, and atomic absorption spectrometers and Raman spectrometers. The plants housed integrated research, engineering, production (optical and electronic) and support facilities. In the early 1990s, partnered with Cetus Corporation (and later Hoffmann-La Roche) to pioneer the polymerase chain reaction (PCR) equipment industry. Analytical-instruments business was also operated from 1954 to 2001 in Germany, by the Bodenseewerk Perkin-Elmer GmbH located in Überlingen at Lake Constance, and England (Perkin Elmer Ltd) at Beaconsfield in Buckinghamshire.

Computer Systems Division

Perkin-Elmer was involved in computer manufacture for a time. The Perkin-Elmer Computer Systems Division was formed through the purchase of Interdata, Inc., an independent computer manufacturer, in 1973–1974 for some US$63 million. This merger made Perkin-Elmer's annual sales rise to over US$200 million. This was also known as Perkin-Elmer's Data Systems Group. The 32-bit computers were very similar to an IBM System/370, but ran the OS/32MT operating system. In 1976, Perkin-Elmer acquired Wangco, a Los Angeles manufacturer of tape drives for $30 million in a stock swap.

The Computer Systems Division had a large presence in Monmouth County, New Jersey, with some 1,700 staff making it one of the county's largest private employers. Its plant in Oceanport had 800 employees alone. By the early-mid-1980s the computing group had sales of $259 million; while profitable, it tended to have reduced visibility within the computing industry due to being owned by a diversified parent.

The Wollongong Group provided the commercial version of the Unix port to the Interdata 7/32 hardware, known as Edition 7 Unix. The port was originally done by the University of Wollongong in New South Wales, Australia, and was the first UNIX port to hardware other than the Digital Equipment Corporation PDP family. By 1982, the Wollongong Group Edition 7 Unix and Programmer's Workbench (PWB) were available on models such as the Perkin-Elmer 3210 and 3240 minicomputers.

In 1985, the computing division of Perkin-Elmer was spun off as Concurrent Computer Corporation, with the goal of giving it and the parallel processing product a clearer identification within the computer industry. At first, the new company was a wholly owned subsidiary of Perkin-Elmer, but with the intentions of putting a minority ownership in the company up for a public stock sale. This was done one in February 1986, with Perkin-Elmer retaining an 82 percent stake in Concurrent. In 1988, there was a merger between Concurrent Computer Corporation and MASSCOMP; as part of the deal, Perkin-Elmer's share in Concurrent was bought out. At that point, Perkin-Elmer said they had culminated their multi-year process of exiting from computer market, allowing them to focus on their primary business segments.

1999

Modern PerkinElmer traces its history back to a merger between divisions of what had been two S&P 500 companies, EG&G Inc. (formerly NYSE: EGG) of Wellesley, Massachusetts and Perkin-Elmer (formerly NYSE: PKN) of Norwalk, Connecticut. On May 28, 1999, the non-government side of EG&G Inc. purchased the Analytical Instruments Division of Perkin-Elmer, its traditional business segment, for US$425 million, also assuming the Perkin-Elmer name and forming the new PerkinElmer company, with new officers and a new board of directors. At the time, EG&G made products for diverse industries including automotive, medical, aerospace and photography.

The old Perkin-Elmer Board of Directors and Officers remained at that reorganized company under its new name, PE Corporation. It had been the Life Sciences division of Perkin-Elmer, and its two component tracking stock business groups, Celera Genomics (NYSE: CRA) and PE Biosystems (formerly NYSE: PEB), were centrally involved in the highest profile biotechnology events of the decade, the intense race against the Human Genome Project consortium, which then resulted in the genomics segment of the technology bubble. Perkin-Elmer purchased the Boston operations of NEN Life Sciences in 2001.

Recently

In 1992, the company merged with Applied Biosystems. In 1997 they merged with PerSeptive Biosystems. On July 14, 1999, the new analytical instruments maker PerkinElmer cut 350 jobs, or 12%, in its cost reduction reorganization. In 2006, PerkinElmer sold off the Fluid Sciences division for approximately US$400 million; the aim of the selloff was to increase the strategic focus on its higher-growth health sciences and photonic markets. Following on from the selloff, a number of small businesses were acquired, including Spectral Genomics, Improvision, Evotec-Technologies, Euroscreen, ViaCell, and Avalon Instruments. The brand "Evotec-Technologies" remains the property of Evotec, the former owner company. PerkinElmer had a license to use the brand until the end of year 2007.

PerkinElmer has continued to expand its interest in medicine with the acquisitions of clinical laboratories, In July 2006, it acquired NTD Labs located on Long Island, New York. The laboratory specializes in prenatal screening during the first trimester of pregnancy. In 2007, it purchased ViaCell, Inc. for US$300 million, which included its offices in Boston and cord blood storage facility in Kentucky near Cincinnati. The company was renamed ViaCord.

In 2001 Perkin Elmer acquired Packard Bioscience Inc from its majority shareholder, Dick McKernen. This acquisition also came with Agincourt Technologies Inc and consolidated Perkin Elmer's position in laboratory robotics, in particular, liquid handling robots which were to prove essential for the high-throughput sequencing needed for the Human Genome Project.

In March 2008, PerkinElmer purchased Pediatrix Screening (formerly Neo Gen Screening), a laboratory located in Bridgeville, Pennsylvania specializing in screening newborns for various inborn errors of metabolism such as phenylketonuria, hypothyroidism, and sickle-cell disease. It renamed the laboratory PerkinElmer Genetics, Inc.

In May 2011, PerkinElmer announced the signature of an agreement to acquire CambridgeSoft, and the successful acquisition of ArtusLabs.

In September 2011, PerkinElmer bought Caliper Life Sciences for US$600 million.

In December 2014 PerkinElmer acquired Perten Instruments for US$266 million to expand in food testing.

In January 2016, PerkinElmer acquired Swedish firm Vanadis Diagnostics.

In February 2016 PerkinElmer acquired Delta Instruments.

In January 2017, the company announced it would acquire the Indian in vitro diagnostic company, Tulip Diagnostics. In May 2017, the company acquired Euroimmun Medical Laboratory Diagnostics for approximately US$1.3 billion.

In 2018, the company acquired Australian biotech company, RHS Ltd., Chinese manufacturer of analytical instruments, Shanghai Spectrum Instruments Co. Ltd., and France-based company Cisbio Bioassays, which specializes in diagnostics and drug discovery solutions.

In November 2020, PerkinElmer announced it would acquire Horizon Discovery Group for around US$383 million.

In March 2021, PerkinElmer announced that the company has completed its acquisition of Oxford Immunotec Global PLC (Oxford Immunotec). In May of the same year, the business announced it would purchase Nexcelom Bioscience for $260 million and Immunodiagnostic Systems Holdings PLC for $155 million. In June the company announced it would acquire SIRION Biotech, a specialist in viral vector gene delivery methods. In July the business announced it would acquire BioLegend for $5.25 billion.

Acquisition history

Programs

Hubble optics project

Perkin-Elmer's Danbury Optical System unit was commissioned to build the optical components of the Hubble Space Telescope. The construction of the main mirror began in 1979 and completed in 1981. The polishing process ran over budget and behind schedule, producing significant friction with NASA. Due to a miscalibrated null corrector, the primary mirror was also found to have a significant spherical aberration after reaching orbit on STS-31. Perkin-Elmer's own calculations and measurements revealed the primary mirror's surface discrepancies, but the company chose to withhold that data from NASA. A NASA investigation heavily criticized Perkin-Elmer for management failings, disregarding written quality guidelines, and ignoring test data that revealed the miscalibration. Corrective optics were installed on the telescope during the first Hubble service and repair mission STS-61. The correction, Corrective Optics Space Telescope Axial Replacement, was applied entirely to the secondary mirror and replaced existing instrumentation; the aberration of the primary mirror remained uncorrected.

The company agreed to pay US$15 million, essentially forgoing its fees in polishing the mirror, to avoid a threatened liability lawsuit under the False Claims Act by the Federal government. Hughes Aircraft, which acquired the Danbury Optical System unit one month after the launch of the telescope, paid US$10 million. The Justice Department asserted that the companies should have known about the flawed testing. Trade group Aerospace Industries Association protested when concerns were raised in the aerospace industry that aerospace companies might be held liable for failed equipment.

KH-9 Hexagon

Perkin-Elmer built the optical systems for the KH-9 Hexagon series of spy satellites at a facility in Danbury, Connecticut.

Source: Wikipedia, CC BY-SA 4.0 · View on Wikipedia ↗

Wikidata ↗

sectorHealthcare industryLife Sciences Tools & Services employees11,000 countryUS

10-Year Performance Revenue, net income, margins and EPS trends

06
Revenue$2.86B
2017-01-01 → 2025-12-28
EPS$2.07
2017-01-01 → 2025-12-28
Free Cash Flow$509M
2017-01-01 → 2025-12-28
Net margin8.5%
2017-01-01 → 2025-12-28
Valuation & Ratios 07–12

Valuation P/E, P/S, P/B, EV/EBITDA ratios — is the stock expensive or cheap?

Metric 5Y trend RVTY 5Y avg Peer Median Verdict
P/E 46.75Y avg ≈34.7 ≈34.7 46.0 Overvalued
P/S 3.85Y avg ≈5.1 ≈5.1 7.1 Undervalued
P/B (MRQ) 2.35Y avg ≈2.2 ≈2.2 6.8 Undervalued
EV / EBITDA 17.35Y avg ≈19.0 ≈19.0 25.4 Undervalued
Price / FCF 21.35Y avg ≈291.5 ≈291.5 · ·
Price / Cash Flow 18.65Y avg ≈46.4 ≈46.4 28.0 Undervalued
EV / Revenue 4.65Y avg ≈6.1 ≈6.1 · ·
EV / FCF 25.85Y avg ≈341.5 ≈341.5 · ·
Price / Tangible Book (MRQ) 3.4 · · ·

Peer median is calculated on a standardized basis per metric and may not always match the TTM/MRQ basis shown for this stock.

value · ≈ 5Y avg · industry median · verdict relative to median

Dividends Yield, payout ratio, dividend history, 5Y CAGR

13
Dividend Yield0.30%
Payout Ratio13.6%
Annualized Payout≈$0.28Paid quarterly
5Y Div CAGR≈0.00%Per share, split-adjusted
Ex-dateAmountCurrencyYield
Jul 17, 2026$0.07USD≈0.25%
Apr 17, 2026$0.07USD≈0.30%
Jan 16, 2026$0.07USD≈0.25%
Oct 17, 2025$0.07USD≈0.30%
Jul 18, 2025$0.07USD≈0.30%
Apr 17, 2025$0.07USD≈0.30%
Jan 17, 2025$0.07USD≈0.24%
Oct 18, 2024$0.07USD≈0.23%
Jul 19, 2024$0.07USD≈0.26%
Apr 18, 2024$0.07USD≈0.28%
Jan 18, 2024$0.07USD≈0.26%
Oct 19, 2023$0.07USD≈0.28%
Jul 20, 2023$0.07USD≈0.22%
Apr 20, 2023$0.07USD≈0.21%
Jan 19, 2023$0.07USD≈0.21%
Oct 20, 2022$0.07USD≈0.22%
Jul 21, 2022$0.07USD≈0.19%
Apr 21, 2022$0.07USD≈0.18%
Jan 20, 2022$0.07USD≈0.16%
Oct 21, 2021$0.07USD≈0.16%

Earnings History EPS actual vs estimate, surprise %, beat rate, next earnings date

14
Avg Surprise 5.0%
Next Report Oct 26, 2026
PeriodReportEPS ActualEPS EstSurprise
June 30, 2026 Jul 27, 2026 $1.41 $1.25 13.1%
March 31, 2026 $1.06 $1.04 2.3%
Dec. 31, 2025 $1.70 $1.58 7.4%
Sept. 30, 2025 $1.18 $1.16 1.7%
June 30, 2025 $1.18 $1.16 1.5%
March 31, 2025 $1.01 $0.97 4.3%

Full Fundamentals All metrics by year — income statement, balance sheet, cash flow

15
Income Statement 17
Metric Trend 202520242023202220212020201920182017201620152014
Revenue $2.86B$2.76B$2.75B$3.31B$3.83B$3.78B$2.88B$2.78B$2.26B$2.12B$2.10B$2.24B
Cost of Revenue ·······$1.44B$709M$665M$696M$708M
Gross Profit ···$1.99B$2.43B$2.11B$1.40B$1.34B$1.07B$1.01B$964M$1.00B
R&D Expense $216M$197M$217M$222M$200M$146M$189M$194M$139M$124M$113M$108M
SG&A Expense $992M$994M$1.02B$1.03B$975M$716M$815M$812M$626M$590M$587M$648M
Operating Income $357M$347M$301M$743M$1.26B$867M$362M$324M$296M$295M$251M$165M
Interest Expense ·····$50M$64M$67M$44M$42M$38M$36M
Interest Income $31M$73M$72M$4M$2M$1M$1M$1M$3M$702.0K$673.0K$667.0K
Other Non-op $-88M$-31M$-118M$-91M$-3M$-5M$-6M$-13M$43M$-15M$-5M$-6M
Pretax Income $268M$316M$183M$652M$1.20B$800M$237M$258M$297M$244M$209M$124M
Income Tax $28M$33M$3M$139M$314M$170M$9M$20M$140M$28M$20M$-6M
Net Income $241M$270M$693M$569M$943M$728M$228M$238M$293M$234M$212M$158M
EPS (Basic) $2.07$2.21$5.56$4.51$8.12$6.52$2.06$2.15$2.67$2.14$1.89$1.40
EPS (Diluted) $2.07$2.20$5.55$4.50$8.08$6.49$2.04$2.13$2.64$2.12$1.87$1.39
Shares (Basic) 116,542,000122,756,000124,704,000126,155,000116,165,000111,514,000110,827,000110,561,000109,857,000109,478,000112,507,000112,593,000
Shares (Diluted) 116,595,000122,822,000124,812,000126,426,000116,674,000112,085,000111,501,000111,534,000110,859,000110,313,000113,315,000113,739,000
EBITDA $762M$775M$732M$1.17B$1.69B$1.23B$576M$504M$410M$383M$398M$327M
Balance Sheet 28
Metric Trend 202520242023202220212020201920182017201620152014
Cash & Equivalents $920M$1.16B$913M$454M$603M$387M$192M$163M$202M$359M$238M$175M
Short-term Investments ·$0$690M$0········
Receivables $745M$632M$633M$613M$708M$1.16B$725M$633M$552M$426M$415M$471M
Inventory $379M$368M$428M$405M$426M$515M$357M$338M$352M$247M$259M$285M
Other Current Assets $196M$186M$337M$122M$148M$167M$100M$101M$94M$99M$64M$138M
Current Assets $2.24B$2.35B$3.00B$3.29B$2.44B$2.24B$1.37B$1.23B$1.20B$1.19B$1.03B$1.07B
PP&E (Net) $479M$482M$510M$483M$486M$368M$318M$319M$298M$145M$138M$176M
PP&E (Gross) $1.09B$982M$983M$857M$844M$818M$702M$680M$631M$428M$402M$493M
Accum. Depreciation $614M$500M$473M$374M$359M$450M$383M$362M$333M$282M$264M$317M
Goodwill $6.61B$6.46B$6.53B$6.48B$6.63B$2.64B$3.11B$2.95B$3.00B$2.25B$2.24B$2.24B
Intangibles $2.35B$2.64B$3.02B$3.38B$3.82B$1.37B$1.28B$1.20B$1.35B$420M$486M$490M
Other Non-current Assets $323M$288M$343M$311M$317M$333M$284M$270M$244M$205M$198M$107M
Total Assets $12.17B$12.39B$13.56B$14.13B$15.00B$7.96B$6.54B$5.98B$6.09B$4.28B$4.17B$4.13B
Accounts Payable $185M$167M$204M$273M$325M$327M$236M$221M$222M$168M$141M$174M
Accrued Liabilities $557M$485M$524M$528M$679M$944M$503M$529M$501M$400M$382M$403M
Current Liabilities $1.33B$653M$1.45B$1.54B$1.21B$1.65B$763M$772M$951M$603M$561M$597M
Capital Leases $148M$152M$133M$170M$147M$188M$146M$0····
Deferred Tax ···········$30M
Other Non-current Liabilities $807M$771M$931M$1.11B$1.43B$775M$751M$742M$849M$460M$465M$443M
Total Liabilities $4.92B$4.73B$5.69B$6.75B$7.86B$4.22B$3.72B$3.39B$3.59B$2.12B$2.06B$2.09B
Long-term Debt $3.22B$3.15B$3.90B$4.39B$4.98B$1.99B$2.07B$1.89B$2.01B$1.05B$480M$1.05B
Total Debt $3.22B$3.15B$3.90B$4.39B$4.98B$1.61B$2.06B$1.88B$1.79B$1.05B$1.01B$1.05B
Common Stock $112M$121M$123M$126M$126M$112M$111M$111M$110M$110M$112M$112M
Retained Earnings $6.05B$5.85B$5.61B$4.95B$4.42B$3.51B$2.81B$2.60B$2.38B$2.12B$1.99B$1.81B
AOCI $-222M$-396M$-277M$-447M$-163M$-32M$-200M$-176M$-47M$-101M$-46M$25M
Stockholders' Equity $7.25B$7.67B$7.87B$7.38B$7.14B$3.74B$2.81B$2.58B$2.50B$2.15B$2.11B$2.04B
Liabilities + Equity $12.17B$12.39B$13.56B$14.13B$15.00B$7.96B$6.54B$5.98B$6.09B$4.28B$4.17B$4.13B
Shares Outstanding 112,281,000120,646,0000126,300,000126,241,000112,090,000111,140,000110,361,000110,361,000109,617,000112,481,000112,481,000
Cash Flow 17
Metric Trend 202520242023202220212020201920182017201620152014
D&A $405M$428M$432M$427M$311M$202M$214M$181M$105M$100M$105M$110M
Stock-based Comp $23M$38M$41M$52M$30M$27M$32M$29M$25M$17M$17M$14M
Deferred Tax $-61M$-102M$-124M$-106M$-55M$-35M$-61M$-51M$29M$-5M$-10M$-34M
Amort. of Intangibles $336M$359M$365M$371M$257M$161M$164M$136M$74M$72M$77M$81M
Restructuring ·$18M$27M$14M$-14M$8M$29M$11M$13M$5M$14M$13M
Other Non-cash $-25M$-6M$-951M$-262M$126M$-82M$-48M$-85M$-163M$4M$-48M$26M
Operating Cash Flow $583M$628M$91M$680M$1.41B$892M$363M$311M$288M$351M$287M$282M
CapEx $74M$87M$81M$86M$86M$64M$76M$93M$39M$32M$28M$27M
Investing Cash Flow $-17M$776M$1.31B$-133M$-4.11B$-504M$-488M$-160M$-1.27B$-84M$-101M$-296M
Stock Repurchased $821M$370M$389M$81M$73M$7M$6M$57M$4M$152M$76M$66M
Net Stock Activity $-821M$-370M$-389M$-81M$-73M$-7M$-6M$-57M$-4M$-152M$-76M$-66M
Dividends Paid $33M$34M$35M$35M$32M$31M$31M$31M$31M$31M$32M$32M
Financing Cash Flow $-858M$-1.13B$-947M$-662M$2.94B$-203M$-150M$-179M$782M$-115M$-107M$31M
Net Change in Cash $-243M$250M$444M$-149M$217M$211M$26M$-36M$-174M$138M$63M$2M
Taxes Paid $131M···········
Free Cash Flow $509M$542M$10M$594M$1.31B$815M$287M$218M$249M$319M$257M$253M
Levered FCF ·····$775M$226M$156M$226M$282M$224M$218M
Profitability 8
Metric Trend 202520242023202220212020201920182017201620152014
Gross Margin ···60.1%·55.8%48.4%48.3%47.5%47.9%45.3%44.9%
Operating Margin 12.5%12.6%10.9%22.4%26.3%25.9%12.6%11.7%13.5%13.4%12.7%9.4%
Net Margin 8.5%9.8%25.2%17.2%18.6%19.2%7.9%8.6%13.0%11.1%9.4%7.0%
Pretax Margin 9.4%11.5%6.7%19.7%25.3%24.0%8.2%9.3%13.2%11.5%10.8%7.6%
EBITDA Margin 26.7%28.1%26.6%35.3%33.4%32.4%20.0%18.2%18.2%18.1%17.6%14.6%
ROA 2.0%2.1%5.0%3.9%8.2%10.0%3.6%3.9%5.6%5.5%5.1%3.9%
ROE 3.3%3.5%8.9%7.9%13.4%20.9%8.2%9.2%12.6%11.0%10.2%7.8%
ROIC 3.0%2.9%2.5%5.0%8.1%14.7%7.1%6.7%3.8%7.8%8.0%6.5%
Liquidity & Solvency 5
Metric Trend 202520242023202220212020201920182017201620152014
Current Ratio 1.73.62.12.12.01.41.81.61.32.01.81.8
Quick Ratio 1.32.71.50.71.40.91.21.00.81.31.21.1
Debt / Equity 0.40.40.50.60.70.40.70.70.70.50.50.5
LT Debt / Equity 0.40.40.40.50.70.40.70.70.70.50.50.5
Interest Coverage ·····19.75.74.86.96.87.55.8
Efficiency 3
Metric Trend 202520242023202220212020201920182017201620152014
Asset Turnover 0.20.20.20.20.40.50.50.50.40.50.50.6
Inventory Turnover ·······4.22.42.62.82.9
Receivables Turnover 4.14.44.45.04.74.04.24.74.65.05.04.8
Per Share 6
Metric Trend 202520242023202220212020201920182017201620152014
Book Value / Share $64.57$63.55$63.79$58.46$56.57$33.33$25.44$23.37$22.68$19.22$18.84$18.16
Revenue / Share $24.50$22.43$22.04$26.20$43.43$33.75$25.86$24.91$20.36$19.18$19.97$19.67
Cash Flow / Share $5.00$5.12$0.73$5.38$12.09$7.96$3.26$2.79$2.60$3.18$2.53$2.48
Cash / Share $8.19$9.64$7.40$3.60$4.90$3.59$1.73$1.47$1.83$3.21$2.12$1.55
Dividend / Share $0.28$0.28$0.28$0.28·$0.28$0.28$0.28$0.28$0.28$0.28$0.28
EPS (TTM) $2.07$2.20$5.55$4.50$8.08$6.49$2.04$2.13$2.64$2.12$1.87$1.39
Growth Rates 10
Metric Trend 202520242023202220212020201920182017201620152014
Revenue YoY 3.7%0.16%-17.0%-13.5%1.2%·······
Revenue CAGR 3Y -4.8%-10.4%-10.1%·········
Revenue CAGR 5Y -5.5%···········
EPS YoY -5.9%-60.4%23.3%-44.3%24.5%·······
EPS CAGR 3Y -22.8%-35.2%-5.1%·········
EPS CAGR 5Y -20.4%···········
Net Income YoY -10.8%-61.0%21.8%-39.6%29.6%·······
Net Income CAGR 3Y -24.9%-34.1%-1.6%·········
Net Income CAGR 5Y -19.8%···········
Dividends Paid CAGR 5Y 1.0%···········
Valuation (TTM) 16
Metric Trend 202520242023202220212020201920182017201620152014
Revenue TTM $2.86B$2.76B$2.75B$3.31B$3.83B$3.78B$2.88B$2.78B$2.26B$2.12B$2.10B$2.24B
Net Income TTM $241M$270M$693M$569M$943M$728M$228M$238M$293M$234M$212M$158M
Market Cap $10.86B$13.51B$13.49B$17.71B$25.38B$16.08B$10.73B$8.55B$8.07B$5.84B$6.00B$4.96B
Enterprise Value $13.16B$15.50B$15.79B$21.65B$29.74B$17.29B$12.61B$10.26B$9.66B$6.53B$6.78B$5.83B
P/E 46.750.919.731.224.922.147.636.327.724.628.631.7
P/S 3.84.94.95.36.64.33.73.13.62.82.92.2
P/B 1.51.81.72.43.64.33.83.33.22.72.82.4
P / Cash Flow 18.621.5147.826.118.018.029.527.528.016.720.917.6
P / FCF 21.324.91362.229.819.419.737.439.232.418.323.319.6
EV / EBITDA 17.320.021.618.517.614.121.920.323.617.017.017.8
EV / FCF 25.828.61594.136.422.721.243.947.138.720.526.323.1
EV / Revenue 4.65.65.76.57.84.64.43.74.33.13.22.6
Dividend Yield 0.30%0.26%0.26%0.20%0.13%0.19%0.29%0.36%0.38%0.53%0.53%0.64%
Earnings Yield 2.1%2.0%5.1%3.2%4.0%4.5%2.1%2.8%3.6%4.1%3.5%3.1%
Payout Ratio 13.6%12.7%5.0%6.2%3.4%4.3%13.7%13.0%10.5%13.2%14.9%20.0%
Annual Payout $33M$34M$35M$35M$32M$31M$31M$31M$31M$31M$32M$32M

Most recent period on the left · null values shown as ·

Financial Statements Income statement, balance sheet, cash flow — annual, last 5 years

16
Metric 2025-12-282024-12-292023-12-312023-01-012022-01-02
Revenue $2.86B $2.76B $2.75B $3.31B $3.83B
Gross Margin % · · · 60.1% ·
Operating Margin % 12.5% 12.6% 10.9% 22.4% 26.3%
Net Income $241M $270M $693M $569M $943M
Diluted EPS $2.07 $2.20 $5.55 $4.50 $8.08

Institutional owners (13F) 579 filers · $11.1B total · As of Sept. 30, 2026

17

Institutions that report holding this stock in their quarterly SEC Form 13F. Long positions only; a single filer may appear twice for separate option legs. Large offsetting put/call legs typically reflect market-making or hedged inventory, not directional conviction.

Holders 579
Value held $11.1B
New positions 101
Exited positions 53
Institutional activity — Q2 2026 vs prior quarter
New positions Exited positions Increased Decreased Net shares change
101 (+19 vs prior Q) 53 (-14 vs prior Q) 195 (+16 vs prior Q) 163 (+4 vs prior Q) -8.8M

Compared to Q1 2026. SEC Form 13F filings are due within 45 days of quarter-end plus a short buffer for late filers — quarters still inside that window are skipped in favor of the most recent fully-reported pair.

Institution Value Shares % of tracked 13F Type
VANGUARD GROUP INC $1,273,316,785 13,160,897 11.42% Shares
EdgePoint Investment Group Inc. $950,658,734 8,544,479 8.53% Shares
BlackRock, Inc. $852,070,090 7,658,369 7.64% Shares
VANGUARD CAPITAL MANAGEMENT LLC $812,306,256 7,300,973 7.29% Shares
JANUS HENDERSON GROUP PLC $731,386,229 8,348,127 6.56% Shares
VANGUARD PORTFOLIO MANAGEMENT LLC $530,760,044 4,770,448 4.76% Shares
STATE STREET CORP $483,173,141 4,342,739 4.33% Shares
VICTORY CAPITAL MANAGEMENT INC $384,362,134 3,454,630 3.45% Shares
DIMENSIONAL FUND ADVISORS LP $381,477,581 3,428,692 3.42% Shares
GEODE CAPITAL MANAGEMENT, LLC $328,197,297 2,955,227 2.94% Shares
MORGAN STANLEY $286,475,399 2,574,826 2.57% Shares
Invesco Ltd. $269,802,164 2,424,970 2.42% Shares
Allspring Global Investments Holdings, LLC $251,393,303 2,227,874 2.25% Shares
NEUBERGER BERMAN GROUP LLC $208,728,363 1,876,041 1.87% Shares
UBS Group AG $207,440,264 1,864,464 1.86% Shares
Pictet Asset Management Holding SA $181,501,112 1,631,343 1.63% Shares
CITADEL ADVISORS LLC $162,143,092 1,457,335 1.45% Shares
RGM Capital, LLC $147,000,789 1,519,388 1.32% Shares
CHARLES SCHWAB INVESTMENT MANAGEMENT INC $120,784,746 1,085,608 1.08% Shares
VAUGHAN NELSON INVESTMENT MANAGEMENT, L.P. $120,187,725 1,080,242 1.08% Shares
NORTHERN TRUST CORP $105,092,080 944,563 0.94% Shares
GOLDMAN SACHS GROUP INC $100,173,074 900,351 0.90% Shares
WELLINGTON MANAGEMENT GROUP LLP $96,303,874 865,575 0.86% Shares
NORGES BANK $96,183,046 864,489 0.86% Shares
PRIMECAP MANAGEMENT CO/CA/ $94,921,470 853,150 0.85% Shares
BANK OF AMERICA CORP /DE/ $87,116,298 782,997 0.78% Shares
Bank of New York Mellon Corp $78,765,533 707,941 0.71% Shares
VANGUARD FIDUCIARY TRUST CO $69,620,945 625,750 0.62% Shares
JANE STREET GROUP, LLC $64,087,317 576,014 0.57% Shares
JPMORGAN CHASE & CO $54,177,057 481,955 0.49% Shares
FMR LLC $51,807,384 465,642 0.46% Shares
SEI INVESTMENTS CO $48,628,856 437,074 0.44% Shares
Quantinno Capital Management LP $47,076,898 423,125 0.42% Shares
DEUTSCHE BANK AG\ $45,437,583 408,391 0.41% Shares
FEDERATED HERMES, INC. $43,043,267 386,871 0.39% Shares
Diamond Hill Capital Management, LLC (Investment Advisor) $42,868,033 385,296 0.38% Shares
UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC $41,752,209 476,569 0.37% Shares
MANUFACTURERS LIFE INSURANCE COMPANY, THE $41,048,042 368,938 0.37% Shares
Freestone Grove Partners LP $36,716,134 330,003 0.33% Shares
Legal & General Group Plc $31,388,230 282,116 0.28% Shares
CIBC Bancorp USA Inc. $29,112,955 261,625 0.26% Shares
Nuveen, LLC $27,202,014 244,491 0.24% Shares
California Public Employees Retirement System $27,021,271 242,866 0.24% Shares
BNP PARIBAS FINANCIAL MARKETS $25,920,242 232,970 0.23% Shares
WEDGE CAPITAL MANAGEMENT L L P/NC $25,784,587 294,311 0.23% Shares
Vanguard Global Advisers, LLC $25,557,201 229,707 0.23% Shares
Swiss National Bank $24,955,618 224,300 0.22% Shares
CIBC Private Wealth Group LLC $23,946,556 273,207 0.21% Shares
Artisan Partners Limited Partnership $22,320,536 200,616 0.20% Shares
Meridiem Capital Partners LP $21,483,638 193,094 0.19% Shares

Show all 579 institutional owners →

Activists & 5%+ owners 2 positions

18

Investors who filed SEC Schedule 13D — beneficial ownership above 5% with an intent to influence the issuer (activist stakes, board campaigns, M&A). Each row shows the most recent known state of that filer's position.

Filer Filed Stake Status Purpose Filing
PERKINELMER, INC. Sept. 16, 2011 · Initial filing M&A / sale SEC
Undisclosed reporting person July 23, 2001 · Initial filing M&A / sale SEC

Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.

Company insiders 46 insiders · 27 officers · 20 directors

19
Insider Role Last activity Shares owned Buys 12m Sells 12m Net 12m
Robert F Friel Chairman and CEO Feb. 13, 2019 F 570,662 0 0 $0
Maxwell Krakowiak Senior Vice President and Chief Financial Officer Sept. 21, 2026 S 14,781 0 1 $-235,728
James M Mock Senior Vice President and Chief Financial Officer June 24, 2022 S 27,577 0 0 $0
Frank Anders Wilson Senior Vice President and Chief Financial Officer March 5, 2018 M 61,925 0 0 $0
Jeffrey D Capello SVP & CFO Jan. 29, 2008 A 91,428 0 0 $0
John Patrick Murphy Chief Operating Officer Aug. 1, 2005 M 68,589 0 0 $0
Anita Gonzales VP and CAO Oct. 1, 2026 S 7,117 0 3 $-29,790
Tajinder Vohra Senior Vice President, Global Operations Sept. 16, 2026 S 6,635 0 2 $-1,634,152
Joel S Goldberg Senior Vice President, Administration, General Counsel and Secretary Aug. 14, 2026 G 91,494 0 4 $-1,274,357
Miriame Victor Senior Vice President, Chief Commercial Officer Feb. 24, 2026 M 18,122 0 1 $-180,856
Daniel R Tereau Senior Vice President, Strategy and Business Development Feb. 5, 2024 A 13,246 0 0 $0
Andrew Okun Vice President, Chief Accounting Officer and Treasurer April 13, 2023 M 4,356 0 0 $0
Deborah A. Butters Senior Vice President, Chief Human Resources Officer Feb. 7, 2020 F 12,383 0 0 $0
James Corbett Executive Vice President and President, Discovery & Analytical Solutions April 30, 2019 F 40,531 0 0 $0
Jonathan P. Divincenzo Senior Vice President and President, Environmental Health Feb. 9, 2016 A 23,158 0 0 $0
John R Letcher Senior Vice President, Human Resources June 5, 2015 D 26,894 0 0 $0
Maurice H. Tenney Senior Vice President, Global Operations and Customer Logistics Nov. 7, 2014 D 12,241 0 0 $0
Daniel R Marshak SVP & CSO Sept. 26, 2014 D 67,743 0 0 $0
Kevin E Hrusovsky Senior Vice President, President Life Sciences and Technology May 31, 2013 D 0 0 0 $0
John A Roush Senior Vice President Feb. 9, 2010 A 120,407 0 0 $0
Richard F Walsh SVP & CAO Jan. 26, 2010 D 183,491 0 0 $0
Gregory L Summe Exe. Chairman of the Board Feb. 27, 2009 S 231,724 0 0 $0
Michael Louis Battles VP & Chief Accounting Officer Feb. 3, 2009 A 33,750 0 0 $0
Katherine A Ohara SVP, Gen. Counsel, & Secretary Jan. 29, 2008 A 65,886 0 0 $0
Peter B Coggins Sr. Vice President Oct. 28, 2005 M 87,070 0 0 $0
Robert A Barrett Sr. Vice President March 3, 2004 M 2,333 0 0 $0
Terrance L Carlson Sr. VP & General Counsel Jan. 27, 2004 J 2,759 0 0 $0
Alexis P. Michas Director Aug. 25, 2026 G 6,985 0 0 $0
Michelle Mcmurry-Heath Director May 7, 2026 A 6,513 0 1 $-58,356
Michael A Klobuchar Director May 7, 2026 A 7,368 0 0 $0
Pascale Witz Director May 7, 2026 A 15,985 0 0 $0
Samuel R. Chapin Director May 7, 2026 A 22,676 0 0 $0
Michel Vounatsos Director May 7, 2026 A 13,977 0 0 $0
Frank Witney Director May 7, 2026 A 23,354 0 0 $0
Sophie V. Vandebroek Director May 7, 2026 A 7,368 0 0 $0
Peter Barrett Director May 7, 2026 A 28,293 0 0 $0
Sylvie Gregoire Director May 15, 2023 A 20,482 0 0 $0
SULLIVAN PATRICK J Director April 30, 2019 A 30,580 0 0 $0
Nicholas A Lopardo Director Feb. 5, 2019 S 39,635 0 0 $0
Vicki L Sato Director Feb. 9, 2017 M 29,970 0 0 $0
Kenton J Sicchitano Director Aug. 24, 2016 M 27,971 0 0 $0
MULLEN JAMES C Director Nov. 14, 2014 M 45,551 0 0 $0
Gabriel Schmergel Director Feb. 16, 2012 M 48,012 0 0 $0
Robert G Tod Director Feb. 14, 2012 M 42,824 0 0 $0
Tamara J Erickson Director Feb. 14, 2007 S 15,352 0 0 $0
Prahlad R. Singh · Aug. 13, 2026 G 59,650 0 5 $-2,557,859

Insiders from SEC Form 3/4/5 filings; net = open-market P/S only

ETF ownership Held by 96 ETFs

20

Weight reflects direct equity holdings (N-PORT) only; leveraged or derivative-based funds may hold additional swap exposure not shown.

Fund Weight Units As of Source
RSPH · Invesco Exchange-Traded Fund Trust 2.02% 115,244 SH Oct. 1, 2026 Daily
HTEC · EXCHANGE TRADED CONCEPTS TRUST 1.13% 6,936 NS July 31, 2026 N-PORT
ALTL · Pacer Funds Trust 0.98% 8,002 NS July 31, 2026 N-PORT
SPHB · Invesco Exchange-Traded Fund Trust … 0.87% 53,854 SH Oct. 1, 2026 Daily
HIBL · Direxion Shares ETF Trust 0.66% 4,421 NS July 31, 2026 N-PORT
IQSM · New York Life Investments ETF Trust 0.50% 14,749 NS July 31, 2026 N-PORT
DFSV · Dimensional ETF Trust 0.43% 313,113 NS July 31, 2026 N-PORT
FXH · First Trust Exchange-Traded AlphaDE… 0.43% 39,813 NS July 31, 2026 N-PORT
JPME · J.P. Morgan Exchange-Traded Fund Tr… 0.36% 14,789 NS July 31, 2026 N-PORT
DFAT · Dimensional ETF Trust 0.35% 444,437 NS July 31, 2026 N-PORT
PKW · Invesco Exchange-Traded Fund Trust 0.34% 37,032 SH Oct. 1, 2026 Daily
BKMC · BNY Mellon ETF Trust 0.32% 18,499 NS July 31, 2026 N-PORT
ESML · iShares Trust 0.29% 66,388 SH Sept. 11, 2026 Daily
BBMC · J.P. Morgan Exchange-Traded Fund Tr… 0.27% 49,018 NS July 31, 2026 N-PORT
VBR · VANGUARD INDEX FUNDS 0.26% 1,624,934 SH Aug. 19, 2026 Daily
RSP · Invesco Exchange-Traded Fund Trust 0.25% 1,580,743 SH Oct. 1, 2026 Daily
IYH · iShares Trust 0.22% 65,502 SH Sept. 11, 2026 Daily
JPUS · J.P. Morgan Exchange-Traded Fund Tr… 0.21% 8,343 NS July 31, 2026 N-PORT
SMMD · iShares Trust 0.19% 59,552 SH Sept. 11, 2026 Daily
BSCT · Invesco Exchange-Traded Self-Indexe… 0.18% 5,732,000 Oct. 1, 2026 Daily
FHLC · FIDELITY COVINGTON TRUST 0.18% 53,129 NS July 31, 2026 N-PORT
VHT · VANGUARD WORLD FUND 0.18% 335,880 SH Aug. 19, 2026 Daily
DFAS · Dimensional ETF Trust 0.18% 241,849 NS July 31, 2026 N-PORT
ISCG · iShares Trust 0.18% 13,989 SH Sept. 11, 2026 Daily
IXJ · iShares Trust 0.17% 58,518 SH Sept. 11, 2026 Daily
REVS · Columbia ETF Trust I 0.17% 4,910 NS July 31, 2026 N-PORT
VB · VANGUARD INDEX FUNDS 0.15% 2,559,509 SH Aug. 19, 2026 Daily
CURE · Direxion Shares ETF Trust 0.14% 2,195 NS July 31, 2026 N-PORT
IWS · iShares Trust 0.13% 167,213 SH Sept. 11, 2026 Daily
WSML · iShares Trust 0.13% 7,071 SH Sept. 11, 2026 Daily
EQAL · Invesco Exchange-Traded Fund Trust … 0.12% 6,239 SH Oct. 1, 2026 Daily
JVAL · J.P. Morgan Exchange-Traded Fund Tr… 0.12% 8,519 NS July 31, 2026 N-PORT
BSCS · Invesco Exchange-Traded Self-Indexe… 0.11% 4,047,000 Oct. 1, 2026 Daily
RECS · Columbia ETF Trust I 0.11% 55,761 NS July 31, 2026 N-PORT
PEXL · Pacer Funds Trust 0.10% 460 NS July 31, 2026 N-PORT
IWR · iShares Trust 0.10% 456,822 SH Sept. 11, 2026 Daily
PFIG · Invesco Exchange-Traded Fund Trust … 0.08% 113,000 Oct. 1, 2026 Daily
XT · iShares Trust 0.08% 25,072 SH Sept. 11, 2026 Daily
XOEF · iShares Trust 0.08% 142 SH Sept. 11, 2026 Daily
FNX · First Trust Exchange-Traded AlphaDE… 0.08% 9,258 NS July 31, 2026 N-PORT
IUS · Invesco Exchange-Traded Self-Indexe… 0.07% 4,175 SH Oct. 1, 2026 Daily
DFAC · Dimensional ETF Trust 0.06% 238,422 NS July 31, 2026 N-PORT
DXUV · Dimensional ETF Trust 0.05% 2,685 NS July 31, 2026 N-PORT
PRF · Invesco Exchange-Traded Fund Trust 0.05% 33,073 SH Oct. 1, 2026 Daily
DFSU · Dimensional ETF Trust 0.05% 10,422 NS July 31, 2026 N-PORT
DFUV · Dimensional ETF Trust 0.05% 65,386 NS July 31, 2026 N-PORT
IVE · iShares Trust 0.05% 185,121 SH Sept. 11, 2026 Daily
IUSV · iShares Trust 0.04% 98,188 SH Sept. 11, 2026 Daily
VOOV · VANGUARD ADMIRAL FUNDS 0.04% 25,806 SH Aug. 19, 2026 Daily
DSI · iShares Trust 0.04% 17,178 SH Sept. 11, 2026 Daily
DCOR · Dimensional ETF Trust 0.04% 11,339 NS July 31, 2026 N-PORT
CHRI · Global X Funds 0.04% 27 NS July 31, 2026 N-PORT
IWD · iShares Trust 0.04% 247,738 SH Sept. 11, 2026 Daily
QVML · Invesco Exchange-Traded Fund Trust … 0.03% 3,353 SH Oct. 1, 2026 Daily
VONV · VANGUARD SCOTTSDALE FUNDS 0.03% 67,429 SH Aug. 19, 2026 Daily
TOPC · iShares Trust 0.03% 72 SH Sept. 11, 2026 Daily
PBP · Invesco Exchange-Traded Fund Trust 0.03% 660 SH Oct. 1, 2026 Daily
TILT · FlexShares Trust 0.02% 4,536 NS July 31, 2026 N-PORT
XVV · iShares Trust 0.02% 1,280 SH Sept. 11, 2026 Daily
DFAU · Dimensional ETF Trust 0.02% 24,920 NS July 31, 2026 N-PORT
PHDG · Invesco Actively Managed Exchange-T… 0.02% 89 SH Sept. 30, 2026 Daily
XYLG · Global X Funds 0.02% 120 NS July 31, 2026 N-PORT
IVV · iShares Trust 0.02% 1,406,050 SH Sept. 11, 2026 Daily
XYLD · Global X Funds 0.02% 5,804 NS July 31, 2026 N-PORT
VOO · VANGUARD INDEX FUNDS 0.02% 2,897,314 SH Aug. 19, 2026 Daily
VTI · VANGUARD INDEX FUNDS 0.02% 3,545,801 SH Aug. 19, 2026 Daily
VONE · VANGUARD SCOTTSDALE FUNDS 0.02% 18,403 SH Aug. 19, 2026 Daily
VTHR · VANGUARD SCOTTSDALE FUNDS 0.02% 9,418 SH Aug. 19, 2026 Daily
ESGV · VANGUARD WORLD FUND 0.02% 25,220 SH Aug. 19, 2026 Daily
IYY · iShares Trust 0.02% 4,913 SH Sept. 11, 2026 Daily
PTLC · Pacer Funds Trust 0.02% 5,733 NS July 31, 2026 N-PORT
IWB · iShares Trust 0.02% 77,050 SH Sept. 11, 2026 Daily
XCLR · Global X Funds 0.02% 6 NS July 31, 2026 N-PORT
ITOT · iShares Trust 0.02% 147,486 SH Sept. 11, 2026 Daily
RWL · Invesco Exchange-Traded Fund Trust … 0.02% 11,723 SH Oct. 1, 2026 Daily
IWV · iShares Trust 0.02% 30,674 SH Sept. 11, 2026 Daily
DFUS · Dimensional ETF Trust 0.02% 33,978 NS July 31, 2026 N-PORT
XRMI · Global X Funds 0.02% 81 NS July 31, 2026 N-PORT
SPUU · Direxion Shares ETF Trust 0.02% 421 NS July 31, 2026 N-PORT
QDPL · Pacer Funds Trust 0.02% 2,684 NS July 31, 2026 N-PORT
XTR · Global X Funds 0.02% 7 NS July 31, 2026 N-PORT
HCMT · Direxion Shares ETF Trust 0.02% 779 NS July 31, 2026 N-PORT
SPXL · Direxion Shares ETF Trust 0.01% 8,723 NS July 31, 2026 N-PORT
OMFL · Invesco Exchange-Traded Self-Indexe… 0.01% 3,445 SH Oct. 1, 2026 Daily
VT · VANGUARD INTERNATIONAL EQUITY INDEX… 0.01% 98,929 SH Aug. 19, 2026 Daily
BIV · VANGUARD BOND INDEX FUNDS · · July 15, 2026 Daily
BLV · VANGUARD BOND INDEX FUNDS · · July 15, 2026 Daily
BSV · VANGUARD BOND INDEX FUNDS · · July 15, 2026 Daily
BND · VANGUARD BOND INDEX FUNDS · · July 15, 2026 Daily
VCSH · VANGUARD SCOTTSDALE FUNDS · · July 15, 2026 Daily
VCIT · VANGUARD SCOTTSDALE FUNDS · · July 15, 2026 Daily
VCLT · VANGUARD SCOTTSDALE FUNDS · · July 15, 2026 Daily
VTC · VANGUARD SCOTTSDALE FUNDS · · July 30, 2026 Daily
BNDW · VANGUARD SCOTTSDALE FUNDS · · July 14, 2026 Daily
ISCB · iShares Trust · 5,032 SH Sept. 11, 2026 Daily
ISCV · iShares Trust · 15,028 SH Sept. 11, 2026 Daily

RVTY Analyst Consensus Bullish and bearish analyst opinions, 12-month price target, upside

21
rating · 25 analysts BUY
Median target $125.50 -17.2%
5 20.0% Strong Buy
8 32.0% Buy
12 48.0% Hold
0 0.0% Sell
0 0.0% Strong Sell

12-Month Price Target

16 analysts · 2026-09-28

Mean target $129.00 -14.9%

Now Current price $151.53
Low$110.00 Mean$129.00 High$165.00

Peer comparison (GICS sub-industry) Key metrics vs sector peers

22

FY basis, prices as of each company's last fiscal year-end close.

Ticker Market Cap P/E Rev YoY Net Margin ROE Gross Margin
RVTY $10.86B 46.7 3.7% 8.5% 3.3% ·
WAT $22.62B 35.3 7.0% 20.3% 27.2% ·
IQV $38.23B 28.8 5.9% 8.3% 21.6% ·
ILMN $20.65B 24.8 -0.66% 19.6% 34.1% 66.1%
MTD $28.38B 33.2 4.0% 21.6% -615.5% 59.4%
WST $19.81B 40.5 6.2% 16.1% 16.2% 35.9%
MEDP $15.93B 36.8 20.0% 17.8% 142.9% ·
TEM · -41.9 83.4% -19.3% -61.2% ·
CRL $10.02B -70.0 -0.85% -3.6% -4.4% ·
TEM · -41.9 83.4% -19.3% -61.2% ·
TXG $2.08B -46.6 5.2% -6.8% -5.5% 69.0%

My Metrics Your personal watchlist — selected rows from Full Fundamentals

26

Pick the metrics that matter to you — click the + next to any row in Full Fundamentals above.

Your selection is saved and follows you across all tickers.

Source: SEC 10-Q filed Aug 11, 2026